Brief Description
The purpose of the study it to measure the effectiveness of the study medication at improving kidney function to prevent damage in people who have IgAN.
Estimated Enrollment
105 participants
Estimated End Date
The estimated end date of enrollment of the study is in the second quarter of 2022
Trial is for people with
A diagnosis of IgAN confirmed by a kidney biopsy with the past 10 years who are on a stable, prescribed regimen of an RAASi (for ...
What is involved for the patient?
Complete assessment like physical exams, blood tests and 24 hour urine. Patients will be assigned to receive active study medication ...
About the drug or intervention
Atacicept is designed to help prevent the buildup of IgA in the kidneys by controlling the immune response that causes IgAN.